Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Z-213 in Iron-deficiency Anemia
NCT02170311Phase 1Completed
- Sponsor
- Zeria Pharmaceutical Co., Ltd.
- Start
- Jun 2014
- Primary completion
- Feb 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of ferric carboxymaltose in iron deficiency anemia (IDA) (4 arms), sponsored by Zeria Pharmaceutical Co., Ltd. Primary endpoints: Pharmacokinetics of total serum iron (Cmax, Tmax, AUC0-t, AUC0-24, AUC0-72, T1/2, CL, Vd, MRT) and total urine iron (CLren, Ae) at 8 days and Safety and Tolerability. Started Jun 2014; status: completed.
02
Drugs
ferric carboxymaltose
03
Conditions
iron deficiency anemia (IDA)
Beyond the preview
Go deeper on NCT02170311.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02170311.